As we advance through each clinical trial phase, we want to offer transparency and insight into our efforts. We have successfully met our endpoints in Phase IIb in 3 separate clinical trials and are currently Phase III ready.
This is where you can find the latest list of clinical trials that Kurve has participated in, for which our next-generation technology was the device of choice.
Clinical stage
We’ve completed our mid-stage clinical trials, and the results met their goals. Next, we’ll meet with the FDA to plan the final stage of testing (Phase 3), which will begin once funding is in place.
TRIAL RESULTS
3
separate clinical trials met their endpoints (Phase 2b)
PUBLISHED RESEARCH
18
peer-reviewed publications
program
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Intranasal insulin
Phase 2 complete · placebo-controlled endpoints met in five trials · Phase 3 planned
Phase 2 complete · placebo-controlled endpoints met in two trials
Phase 2 complete
ALSO STUDIED NOSE-TO-BRAIN WITH THE KURVE DEVICE
ASL
PTSD
Traumatic brain injury
Mood and anxiety disorders
Schizophrenia
Multiple sclerosis
Memory in HIV
Autism
Glioblastoma
Completed
Planned, subject to FDA meeting and funding
All programs are investigational and have not been approved by the FDA. Safety and efficacy have not been established. Stage reflects the most advanced completed step for each indication. Studies include trials run by academic and government sponsors using the Kurve device.
We hold to the highest levels of transparency and integrity when it comes to sharing the results of our ongoing clinical trial phase. So far, we’ve met our endpoints in 3 separate clinical trials (Phase 2b) and are cleared to begin Phase 3. Here’s the latest trials we’ve participated in where our next-generation technology was the device of choice:
Conducted by
01 / 10
ViaNase™ is available through Kurve’s clinical studies and FDA expanded access (compassionate use). Tell us who you are and we’ll guide you to the right route.
